American Society of Anesthesiologists Comments on Fospropofol (Aquavan) NDA 22-244 Open Public Hearing May 7, 2008, meeting of the Anesthetic and Life.

Slides:



Advertisements
Similar presentations
Moderate Sedation & Analgesia
Advertisements

Advances in the Clinical Pharmacology of Intravenous Anesthetics : Pharmacokinetic, Pharmacodynamic, Pharmaceutical, and Technological Considerations R3.
LAKSHMAN KARALLIEDDE OCTOBER 2011
Pharmacology for Anesthesia I Introduction. What is a Drug?
Conscious Sedation: What You Need to Know Michael Sugarman, MD Visiting Professor of Anesthesiology Montefiore Medical Center Albert Einstein College.
Dr. Kelly Mayson, Vancouver Coastal Health.  Select from the list the principle anesthesia technique used  The technique employed may be found on the.
25 TAC Quality Assurance in a licensed ASC
Early Clinical Development High Resolution PK/PD in Phase I to Guide Subsequent Development: Experience with Remifentanil Steven L. Shafer, M.D. Palo Alto.
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH Working with FDA: Biological Products and Clinical Development Critical Path.
Procedural Sedation: Deb Updegraff, R.N., M.S.N. P.N.P. Clinical Nurse Specialist Pediatric Intensive Care 3S Intermediate Intensive Care LPCH.
Procedural Sedation Pharmacology Deb Updegraff R.N., P.N.P, C.N.S. Clinical Nurse Specialist LPCH Pediatric Intensive Care Unit.
Exercise 6 Dose linearity and dose proportionality
Preoperative Anxiety Ilan Keidan MD Pediatric Anesthesia Anesthesia and Intensive Care Sheba Medical Center.
How and Why Drugs Work Chapter 5
Conscious Sedation. Sedation and Analgesia O “ A state that allows patients to tolerate unpleasant procedures while maintaining adequate cardiorespiratory.
2014 Summit Co-Convener:Founder: Patient Safety Science & Technology Summit 2014.
Practice Guidelines for the Prevention, Detection, and Management of Respiratory Depression Associated with Neuraxial Opioid Administration Troy Tada,
Low Resource Anesthesia
Obstructive Sleep Apnea of Obese Adults Obstructive Sleep Apnea of Obese Adults Pathophysiology and Perioperative Airway Management Anesthesiology, 2009,
Situation Awareness Assessment to Determine the Usability of a Graphical Anesthesia Display During a Simulated Anesthetic: Study Results Parley Williams,
Blood Pressure Lability During Cardiac Surgery Is Associated With Adverse Outcomes Solomon Aronson, Edwin G. Avery, Cornelius Dyke, Joseph Varon, Jerrold.
Copyright © 2012, 2011, 2010, 2009, 2008, 2007, 2006, 2005, 2004, 2002 by Saunders, an imprint of Elsevier Inc. Slide 1 CHAPTER 16 ANESTHESIA.
Stanford Plavin MD Vice Chairperson Board Certified Anesthesiologist and Patient Safety Advocate.
INTRAVENOUS INFUSION.
Smart Device Integration
Minimal and Moderate Sedation T. J. Gan, M.B., F.R.C.A., M.H.S., Li. Ac. Professor of Anesthesiology Vice Chair for Clinical Research Duke University Medical.
Responsibilities and Principles of Drug Administration
Stanford R. Plavin MD Vice Chairperson Board Certified Anesthesiologist and Patient Safety Advocate.
Sedation.
Beyond volume of patients: Organizational and professional factors related to hospital outcomes R. Blais, PhD, R. Pineault, MD, PhD, P. Boyle, PhD, S.
Nonclinical Perspective on Initiating Phase 1 Studies for Small Molecular Weight Compounds John K. Leighton, PH.D., DABT Supervisory Pharmacologist Division.
Week 6- Bioavailability and Bioequivalence
The SEDASYS™ Computer- Assisted Personalized Sedation System (CAPS) Steven J. Morris MD JD FACP President, Atlanta Gastroenterology Associates, LLC Director,
Procedural Sedation for Adult Patients. By relieving anxiety, reducing pain, and providing amnesia, sedation techniques have the potential to render potentially.
Copyright © 2008 Lippincott Williams & Wilkins. Introductory Clinical Pharmacology Chapter 21 Anesthetic Drugs.
Issues in Generic Substitution: Safety/Efficacy, Cost Savings and Supply Robert J. Herman, MD, FRCPC Professor, Department of Medicine University of Calgary.
Fospropofol for sedation
CHEE 4401 Definitions drug - any substance that affects the structure or functioning of an organism pharmaceutics - the area of study concerned with the.
Rivaroxaban Has Predictable Pharmacokinetics (PK) and Pharmacodynamics (PD) When Given Once or Twice Daily for the Treatment of Acute, Proximal Deep Vein.
Bioequivalence Dr Mohammad Issa Saleh.
Perioperative Nursing Care
Bioavailability Dr. Basavaraj K. Nanjwade M. Pharm., Ph. D Department of Pharmaceutics Faculty of Pharmacy Omer Al-Mukhtar University Tobruk, Libya.
Reptile Anesthesia.  Injectable and inhalant anesthetics are commonly employed both for surgery and sedation for diagnostic or treatment procedures.
General Regulatory Issues in the Development of Drugs Intended for Treatment of Chronic Illness Sharon Hertz, M.D. Medical Officer Division of Anesthetic,
BIOPHARMACEUTICS.
A Phase 3 Prospective, Randomized, International Study (MMY-3021) Comparing Subcutaneous and Intravenous Administration of Bortezomib in Patients with.
Analgesia and Sedation in Intervention Radiology
Critical Appraisal Topic Acquil Mohammad U. Alip, MD Resident Dept. of Anesthesiology UP-PGH Manila, Philippines.
Initiatives Drive Pediatric Drug Development January 30, 2002.
Clinical Pharmacokinetic Equations and Calculations
INTRODUCTION OF TWO NEW ANESTHETIC AGENTS Dr.G.k.kumar.
Endoscopic Sedation Todd H. Baron, MD, FASGE Chair, ASGE Standards of Practice Committee Professor of Medicine Div. Gastroenterology & Hepatology Mayo.
Clinical Trials - PHASE II. Introduction  Important part of drug discovery process  Why important??  Therapeutic exploratory trial  First time in.
Methods to Adjust Doses Based on Exposure-Response Information Points to Consider Richard Lalonde Clinical Pharmacokinetics and Pharmacodynamics Pfizer.
Mary S. Schaefer, RN, M.Ed, ARM, JD
How and Why Drugs Work Chapter 5
Chapter 8 BIOAVAILABILITY & BIOEQUIVALENCE

Early Clinical Development
Propofol Administration by Non-Anesthesia Providers
Conscious Sedation March, 2012.
Procedural sedation in adults
5 Pharmacodynamics.
Clinical Pharmacokinetics
Clinical Pharmacokinetics
Clinical Pharmacokinetics
M. M. R. F. Struys, M. Sahinovic, B. J. Lichtenbelt, H. E. M
Current Evaluation Process
Role of Anesthesiologists/CRNA in an Office Interventional Suite
Plasma concentration-time profile after oral administration of a single dose. Plasma concentration-time profile after oral administration of a single dose.
Presentation transcript:

American Society of Anesthesiologists Comments on Fospropofol (Aquavan) NDA Open Public Hearing May 7, 2008, meeting of the Anesthetic and Life Support Drugs Advisory Committee Thomas K. Henthorn, MD Professor and Chair Department of Anesthesiology University of Colorado Denver Chair, ASA Subcommittee on Anesthetic Action and Biochemistry

Complexities posed by the Pharmacokinetics and Pharmacodynamics of Fospropofol More interindividual variability in the PKs More interindividual variability in the PKs –Incomplete hydrolysis (unlike similar prodrug fosphenytoin which is complete) –Nonlinear kinetics Lipid-free propofol does not have the same PK/PD profile as the emulsion formulation Lipid-free propofol does not have the same PK/PD profile as the emulsion formulation Steep concentration response curve Steep concentration response curve Synergism with other sedative-hypnotics Synergism with other sedative-hypnotics

Plasma Propofol Following 20 minute infusions of Diprivan and Aquavan Fechner J, Ihmsen H, Hatterscheid D, Jeleazcov C, Schiessl C, Vornov JJ, Schwilden H, Schuttler J Anesthesiology 2004; 101: 626 Aquavan

Plasma Propofol Following 20 minute infusions of Diprivan and Aquavan Gibiansky E, Struys MM, Gibiansky L, Vanluchene AL, Vornov J, Mortier EP, Burak E, Van Bortel L Anesthesiology 2005; 103: 718 Dose escalation 5 mg/kg – 30 mg/kg

Pharmacokinetic Models for Fospropofol and Propofol Anesthesiology 2004; 101: 626 Fechner et al. Anesthesiology 2004; 101: 626 Gibiansky E, et al., Anesthesiology 2005; 103: 718

AQUAVAN® Injection, a Water-soluble Prodrug of Propofol, as a Bolus Injection: A Phase I Dose- escalation Comparison with DIPRIVAN® (Part 2): Pharmacodynamics and Safety Struys MM, Vanluchene AL, Gibiansky E, Gibiansky L, Vornov J, Mortier EP, Van Bortel L Anesthesiology 2005; 103: 730 Equipotency on an equimolar basis Equipotency on an equimolar basis –Fospropofol:Propofol –1.86:1 Actual equipotency to produce similar plasma propofol concentrations Actual equipotency to produce similar plasma propofol concentrations –Fospropofol:Propofol –6.32:1

Fospropofol introduces additional pharmacokinetic variability Dose equivalency of fospropofol with propofol is not on a equimolar basis Dose equivalency of fospropofol with propofol is not on a equimolar basis –Propofol is being ‘lost’ –Cannot discern whether this loss occurs before or after hydrolysis step from the studies to date Apparent fraction hydrolyzed increases with dose Apparent fraction hydrolyzed increases with dose –Leads to an overestimation of the Cmax of propofol at low doses and underestimation at high doses of approximately 43% and 36%, respectively –This nonlinearity creates a potentially ‘dangerous’ situation These conditions strongly argue for the presence of personnel sufficiently educated and trained to deal with the full continuum of sedation and anesthesia These conditions strongly argue for the presence of personnel sufficiently educated and trained to deal with the full continuum of sedation and anesthesia

Lipid-free propofol (from fospropofol) has different pharmacokinetics than lipid emulsion propofol Anesthesiology 2004; 101: 626 Fechner et al. Anesthesiology 2004; 101: 626

Lipid-free propofol (from fospropofol) is more potent than lipid emulsion propofol Anesthesiology 2004; 101: 626 Fechner et al. Anesthesiology 2004; 101: 626

Dose titration The concentration-response relationship for propofol is steep The concentration-response relationship for propofol is steep –The Hill coefficient (gamma) determines the slope or steepness of the sigmoid Emax curve –Midazolam gamma – approximately 0.8 –Propofol gamma – approximately 3.0 This makes propofol dose titration seem unpredictable compared to midazolam This makes propofol dose titration seem unpredictable compared to midazolam

Dose titration

The solution for a steep concentration-response relationship The solution for a steep concentration-response relationship –Administer small fractions of initial dose Current Phase II/III studies for Aquavan do nicely follow this guideline Current Phase II/III studies for Aquavan do nicely follow this guideline –Fospropofol 6.5 mg/kg as initial dose followed by ¼ of this dose (1.6 mg/min) every 4 minutes up to a maximum of 3 repeat doses –‘Sedation failure’ rate of approximately 20% –At least 15 minutes would be required to reach ‘sedation failure’ decision Options at point of ‘sedation failure’ Options at point of ‘sedation failure’ –Cancel procedure –Continue with procedure without adequate sedation –Go ‘off label’ with additional fospropofol –Change sedative drug (e.g., midazolam)

Fospropofol Sedation Success during Colonoscopy Cohen LB. Alimentary Pharmacology & Therapeutics 27 (7), Figure 1. Sedation success. The primary end point of this study was sedation success, where a highly significant dose-dependent trend was observed across fospropofol dosing groups in the modified intent-to-treat population (P < by Cochran–Armitage trend test). The sedation success rates were 24%, 35%, 69% and 96% in the FP 2.0, FP 5.0, FP 6.5 and FP 8.0 groups respectively. *P < 0.05 vs. FP 2.0 and FP 5.0.

Sedative Combinations Produce Variable Synergism Sedative Combinations Produce Variable Synergism Triple anesthetic combination: propofol-midazolam-alfentanil. Vinik HR et al., Anesth Analg 1994; 78: 354

Practice Guidelines for Sedation and Analgesia by Non-Anesthesiologists Anesthesiology: 96(4):1004, 2002

Propofol derived from fospropofol is an anesthetic drug Aquavan has high variability in its conversion to propofol Aquavan has high variability in its conversion to propofol The fraction converted is nonlinear with a higher fraction being converted as dose increases The fraction converted is nonlinear with a higher fraction being converted as dose increases Propofol from Aquavan is more potent (when comparing plasma propofol concentrations) Compared to the standard drug used for sedation (midazolam), propofol concentration-response curve is much steeper – –Making Aquavan more ‘unpredictable’ – –Requiring a very (or impossibly) large educational effort if Aquavan is introduced into the ‘proceduralist’ environment without the presence of personnel trained in the continuum of sedation.

Propofol derived from fospropofol is an anesthetic drug Small initial doses with well-spaced and even smaller repeat doses appeared to be safe in Phase II/III trials But these dosing limitations led to a high ‘sedation failure’ rate. – –Necessitating the addition of midazolam to the fentanyl-propofol regimen – –Adding midazolam to this combination appears to double the synergistic sedative-anesthesia interaction and led to the cases of deep sedation/anesthesia seen during the trials.

Conclusions Propofol, whether administered in a lipid emulsion formulation or as fospropofol (Aquavan) is a powerful anesthetic agent that can produce unpredictable levels of sedation along the continuum from sedation to general anesthesia. Propofol, whether administered in a lipid emulsion formulation or as fospropofol (Aquavan) is a powerful anesthetic agent that can produce unpredictable levels of sedation along the continuum from sedation to general anesthesia.

Conclusions Propofol is efficacious and safe when administered by physicians with the appropriate training and appropriate monitoring technology. Propofol is efficacious and safe when administered by physicians with the appropriate training and appropriate monitoring technology. Because sedation is a continuum and the propofol plasma (or effect site) concentration-response relationship is steep, it is not always possible to predict how an individual patient will respond. Because sedation is a continuum and the propofol plasma (or effect site) concentration-response relationship is steep, it is not always possible to predict how an individual patient will respond. Delayed time to peak effect (as seen with Aquavan) can increase the difficulty of titrating a drug with a steep response curve and narrow margin of safety. Delayed time to peak effect (as seen with Aquavan) can increase the difficulty of titrating a drug with a steep response curve and narrow margin of safety. Patients appear to differ in their individual reactions to a standard dose. Patients appear to differ in their individual reactions to a standard dose. Besides the known approximately 20-fold variation in the rate of metabolism of propofol, there appears to be additional variability in the production of propofol from fospropofol and nonlinear conversion as larger cumulative doses are administered. Besides the known approximately 20-fold variation in the rate of metabolism of propofol, there appears to be additional variability in the production of propofol from fospropofol and nonlinear conversion as larger cumulative doses are administered.

Conclusions There are no antagonist or reversal medications for propofol. There are no antagonist or reversal medications for propofol. Lack of a specific antagonist is an important factor that distinguishes propofol from other sedatives, such as benzodiazepines and narcotics, currently used by non- anesthesiologist physicians. Lack of a specific antagonist is an important factor that distinguishes propofol from other sedatives, such as benzodiazepines and narcotics, currently used by non- anesthesiologist physicians. Due to the potential for rapid, profound changes in sedative/anesthetic depth and the lack of antagonist medications, agents such as propofol require special attention. Due to the potential for rapid, profound changes in sedative/anesthetic depth and the lack of antagonist medications, agents such as propofol require special attention. Even if moderate sedation is intended, patients receiving propofol should receive care consistent with that required for deep sedation. Even if moderate sedation is intended, patients receiving propofol should receive care consistent with that required for deep sedation. This means that the clinician administering propofol must be competent to recognize a state of general anesthesia and rescue a patient experiencing any of the complications of general anesthesia. This means that the clinician administering propofol must be competent to recognize a state of general anesthesia and rescue a patient experiencing any of the complications of general anesthesia.

Conclusions The July 2003 issue of Outpatient Surgery magazine reported 74.8% felt that propofol administration by RNs was a patient-safety risk and 71.2% believed administering anesthesia with propofol to be outside of an RN’s scope of practice. The July 2003 issue of Outpatient Surgery magazine reported 74.8% felt that propofol administration by RNs was a patient-safety risk and 71.2% believed administering anesthesia with propofol to be outside of an RN’s scope of practice. According to the article, many RNs are uncomfortable using propofol, feeling that unpredictable and instantaneous patient reactions such as loss of an airway render administration and monitoring of the drug beyond their competence. According to the article, many RNs are uncomfortable using propofol, feeling that unpredictable and instantaneous patient reactions such as loss of an airway render administration and monitoring of the drug beyond their competence. The American Association for the Accreditation of Ambulatory Surgical Facilities (AAAASF) has explicitly taken the position that propofol, unlike other intravenous sedation, may not be administered by a registered nurse. The American Association for the Accreditation of Ambulatory Surgical Facilities (AAAASF) has explicitly taken the position that propofol, unlike other intravenous sedation, may not be administered by a registered nurse.

Conclusions The Joint Commission on Accreditation of Healthcare Organizations (JCAHO) requires that clinicians intending to administer deep sedation be qualified to rescue patients from general anesthesia and be competent to manage an unstable cardiovascular system as well as a compromised airway and inadequate oxygenation and ventilation. The Joint Commission on Accreditation of Healthcare Organizations (JCAHO) requires that clinicians intending to administer deep sedation be qualified to rescue patients from general anesthesia and be competent to manage an unstable cardiovascular system as well as a compromised airway and inadequate oxygenation and ventilation. The joint ASA/ AANA statement on propofol use indicates that, “personnel who administer propofol should be qualified to rescue patients whose level of sedation becomes deeper than initially intended and who enter, if briefly, a state of general anesthesia.” The joint ASA/ AANA statement on propofol use indicates that, “personnel who administer propofol should be qualified to rescue patients whose level of sedation becomes deeper than initially intended and who enter, if briefly, a state of general anesthesia.”

Conclusions The current labeling for Propofol includes the precaution that the individual who administers the drug should “not [be] involved in the conduct of the surgical/diagnostic procedure.” The current labeling for Propofol includes the precaution that the individual who administers the drug should “not [be] involved in the conduct of the surgical/diagnostic procedure.” Logic and the clinical pharmacology of fospropofol dictated that similar language should be on the label of Aquavan. Logic and the clinical pharmacology of fospropofol dictated that similar language should be on the label of Aquavan.